<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040375</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Enzyme replacement therapy in fabary's disease</dc:title>
<dc:description xml:lang="en">We report a 56-year-old man with history of chronic renal failure, who wasdiagnosed to have Fabry&#146;s disease after performing a percutaneous kidney biopsy.The diagnosis was confirmed by the deficient level of activity of a-galactosidaseA and by the identification of the mutation. A enzime replacement therapy with alfa-galactosidase A was administered. After 18 months of treatment, a second kidneybiopsy was performed showing renal deposits of globotriaosylceramide (wedid not evaluate the percentage of histologic clearance of the deposits). Six monthsafter the end of the therapy, a reduction in the impairment of renal function isobserved, and the classic manifestations of the disease are absent</dc:description>
<dc:creator>Sánchez, L</dc:creator>
<dc:creator>López-Menchero, R</dc:creator>
<dc:creator>Álvarez, L</dc:creator>
<dc:creator>Ortega, E</dc:creator>
<dc:creator>Trigueros, M</dc:creator>
<dc:creator>Albero, M. D</dc:creator>
<dc:creator>Pozo, C. del</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Presentamos el caso de un varón de 56 años, con enfermedad de Fabry diagnosticadatras la realización de biopsia renal por cuadro de insuficiencia renal crónica.La determinación de niveles de actividad enzimática disminuidos de la a-galactosidasaA leucocitaria y la identificación de la mutación, confirmaron eldiagnóstico. Se administra tratamiento de remplazamiento enzimático con alfa-galactosidasa. Tras 18 meses de terapia se ha objetivado un enlentecimiento en elritmo de progresión de la insuficiencia renal crónica, sin aparición de nuevas manifestacionesatribuibles a la enfermedad. Se practicó una segunda biopsia renalobservando que los depósitos de globotriasilceramida persistían tras la terapia</dc:description>
<dc:source>Nefrologia;25(3): 322-327, mayo 2005. ilus</dc:source>
<dc:identifier>ibc-040375</dc:identifier>
<dc:title xml:lang="es">Terapia de sustitución enzimática en la enfermedad de Fabry: evaluación clínico-histológica tras 18 meses de terapia</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d50497^s22027</dc:subject>
<dc:subject>^d28625</dc:subject>
<dc:subject>^d7840^s29165</dc:subject>
<dc:subject>^d7840^s22053</dc:subject>
<dc:subject>^d31710^s22073</dc:subject>
<dc:subject>^d50497^s22053</dc:subject>
<dc:subject>^d31710</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6060^s22002</dc:subject>
<dc:subject>^d30299^s22026</dc:subject>
<dc:subject>^d30299^s22016</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d30299^s22057</dc:subject>
<dc:subject>^d1731</dc:subject>
<dc:subject>^d30299^s22033</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d19333</dc:subject>
<dc:type>article</dc:type>
<dc:date>200505</dc:date>
</metadata>
</record>
</ibecs-document>
